Krishna Pandey Selected Research

Visceral Leishmaniasis (Kala Azar)

10/2022	AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
1/2022	Revealing a Novel Antigen Repressor of Differentiation Kinase 2 for Diagnosis of Human Visceral Leishmaniasis in India.
1/2022	An immunoprophylactic evaluation of Ld-ODC derived HLA-A0201 restricted peptides against visceral leishmaniasis.
10/2021	A Novel Antigen, Otubain Cysteine Peptidase of Leishmania donovani, for the Serodiagnosis of Visceral Leishmaniasis and for Monitoring Treatment Response.
1/2021	Evaluation of qPCR on blood and skin microbiopsies, peripheral blood buffy coat smear, and urine antigen ELISA for diagnosis and test of cure for visceral leishmaniasis in HIV-coinfected patients in India: a prospective cohort study.
1/2021	Improved kala-azar case management through implementation of health facility-based sentinel sites surveillance system in Bihar, India.
1/2021	A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
1/2021	Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis.
10/2020	Evaluation of Cysteine Protease C of Leishmania donovani in Comparison with Glycoprotein 63 and Elongation Factor 1α for Diagnosis of Human Visceral Leishmaniasis and for Posttreatment Follow-Up Response.
1/2020	Advanced case of PKDL due to delayed treatment: A rare case report.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Krishna Pandey Research Topics

Disease

57	Visceral Leishmaniasis (Kala Azar) 10/2022 - 01/2005
16	Infections 10/2021 - 01/2005
12	Leishmaniasis 01/2021 - 03/2008
4	Necrosis 01/2020 - 10/2012
3	Tuberculosis (Tuberculoses) 10/2022 - 01/2005
3	HIV Infections (HIV Infection) 01/2021 - 03/2006
3	Body Weight (Weight, Body) 11/2017 - 08/2010
2	Bites and Stings (Sting) 01/2021 - 01/2005
2	Neoplasms (Cancer) 09/2013 - 03/2008
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2021
1	Uveitis 01/2020
1	Anterior Uveitis 01/2020
1	Cardiomyopathies (Cardiomyopathy) 08/2019
1	Type 2 Diabetes Mellitus (MODY) 08/2019
1	Human Influenza (Influenza) 05/2019
1	Virus Diseases (Viral Diseases) 05/2019
1	Parasitic Diseases (Parasitic Disease) 12/2017
1	Neglected Diseases 01/2017
1	Inflammation (Inflammations) 01/2017
1	Communicable Diseases (Infectious Diseases) 01/2017
1	Asymptomatic Infections 12/2016
1	Vomiting 11/2016
1	Diarrhea 11/2016
1	Dehydration (Water Stress) 11/2016
1	Neoplasm Metastasis (Metastasis) 11/2016
1	Breast Neoplasms (Breast Cancer) 11/2016
1	Drug-Related Side Effects and Adverse Reactions 11/2016

Drug/Important Bio-Agent (IBA)

14	miltefosine (Impavido)IBA 10/2022 - 08/2007
11	Pharmaceutical PreparationsIBA 01/2021 - 02/2011
10	liposomal amphotericin B FDA Link 10/2022 - 08/2010
7	Interleukin-10 (Interleukin 10)IBA 01/2021 - 09/2013
6	AntigensIBA 01/2022 - 01/2017
6	CytokinesIBA 10/2018 - 07/2012
6	Amphotericin B (Amphotericin)FDA LinkGeneric 06/2017 - 02/2009
5	EpitopesIBA 01/2022 - 01/2017
4	VaccinesIBA 01/2021 - 01/2017
4	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 01/2019 - 10/2011
3	Ornithine Decarboxylase (Decarboxylase, Ornithine)IBA 01/2022 - 01/2015
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2017
3	Interleukin-12 (IL 12)IBA 01/2018 - 09/2013
3	AntimonyIBA 02/2012 - 03/2008
2	Peptides (Polypeptides)IBA 01/2022 - 06/2017
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2015
2	trypanothioneIBA 01/2018 - 01/2015
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2015 - 10/2012
2	EnzymesIBA 01/2015 - 07/2012
1	Phosphotransferases (Kinase)IBA 01/2022
1	HLA-A*02:01 antigenIBA 01/2022
1	Cysteine (L-Cysteine)FDA Link 10/2021
1	Peptide Hydrolases (Proteases)FDA Link 10/2021
1	Oxidants (Oxidizing Agents)IBA 10/2021
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 10/2021
1	mevalonate kinaseIBA 01/2021
1	Leishmaniasis VaccinesIBA 01/2021
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2021
1	Glycoproteins (Glycoprotein)IBA 10/2020
1	Peptide Elongation Factors (Elongation Factor)IBA 10/2020
1	Cysteine Proteases (Cysteine Protease)IBA 10/2020
1	Adenosine DeaminaseIBA 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 10/2019
1	Antiviral Agents (Antivirals)IBA 05/2019
1	Viral RNAIBA 05/2019
1	CaspasesIBA 10/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	tryparedoxinIBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2018
1	InterferonsIBA 01/2018
1	Interleukin-2 (IL2)IBA 01/2018
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2018
1	Phosphoglycerate Mutase (Phosphoglyceromutase)IBA 01/2018
1	Interleukin-4 (Interleukin 4)IBA 01/2018
1	ChemokinesIBA 01/2018
1	L-SelectinIBA 01/2018
1	ProteomeIBA 01/2018
1	Subunit VaccinesIBA 01/2018
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018
1	A-Form DNA (A-DNA)IBA 01/2018
1	p38 Mitogen-Activated Protein KinasesIBA 01/2018
1	Granzymes (Granzyme)IBA 01/2018
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 12/2017
1	Dihydrotachysterol (AT 10)IBA 11/2017
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 06/2017
1	ferric oxide (iron oxide)IBA 06/2017
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017
1	Protein Disulfide-IsomerasesIBA 01/2017
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2017
1	polycarbonateIBA 01/2017
1	SaranIBA 12/2016
1	ArsenicIBA 10/2016
1	Adenosine (Adenocard)FDA LinkGeneric 03/2016
1	Purine NucleosidesIBA 03/2016
1	4-O-carboxymethylascochlorinIBA 10/2015
1	PhosphoproteinsIBA 02/2015

Therapy/Procedure

9	Therapeutics 10/2022 - 01/2005
2	Aftercare (After-Treatment) 01/2020 - 04/2012
1	Intradermal Injections 01/2021
1	Intravenous Infusions 11/2017
1	Immunomodulation 01/2017